Sofia

• A study to learn more about how safe finerenone is, when it is taken for a longer time with standard treatment, in children and young adults … Recruiting
  2024-519830-22-00 5 2026-04-27 Heart failure due to systemic left ventricular systolic dysfunction
• Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Recruiting
  2025-522878-36-00 5 2026-04-20 Chronic Spontaneous Urticaria
• A study to learn if bimekizumab given in different ways is safe and moves similarly throughout the body over time in adults Recruiting
  2025-522782-30-00 3 2026-04-07 CCI
• A multi-center evaluation of NGM120 in a randomized, double-blind, placebo-controlled study in participants with colorectal cancer who have … Recruiting
  2025-521730-28-00 4 2026-03-30 Colorectal Cancer with Cancer Cachexia
• Visugromab in Cachexia International Trial Recruiting
  2025-523533-25-00 10 2026-03-26 Cancer-associated Cachexia
• A study to assess the efficacy and safety of empasiprubart in adults with CIDP Recruiting
  2025-520805-10-00 5 2026-03-12 Chronic inflammatory demyelinating polyneuropathy (CIDP)
• Essentiale® liquid once-daily Phase III study Recruiting
  2025-521678-32-00 5 2026-03-03 MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) / MAS
• A study to assess efficacy and safety of empasiprubart versus IVIg in adults with CIDP ("emvigorate") Recruiting
  2024-520097-36-00 5 2026-01-07 Chronic inflammatory demyelinating polyneuropathy (CIDP)
• Evenamide in patients with treatment-resistant schizophrenia not responding to antipsychotics Recruiting
  2024-519836-18-00 5 2025-12-16 treatment-resistant schizophrenia (TRS)
• A study to understand the safety and benefit of AlloNK® with rituximab in patients with hard-to-treat rheumatic diseases Recruiting
  2025-520461-41-00 4 2025-10-22 Systemic Sclerosis (SSc)
• Vedolizumab Subcutaneous Long-term Open-label Extension Study in Pediatric Subjects Recruiting
  2023-508804-39-00 5 2025-10-15 Ulcerative Colitis or Crohn’s Disease
• Long-term study to assess the safety and tolerability of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD) Recruiting
  2024-519423-24-00 5 2025-10-07 Major Depressive Disorder
• Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obe … Recruiting
  2024-520209-38-00 5 2025-09-19 Obesity or Overweight
• A Phase 2 Randomized Trial Evaluating Efficacy of AGA2118 in Postmenopausal Women with Low Bone Mass (ARTEMIS) Recruiting
  2024-515610-41-00 4 2025-09-11 Postmenopausal Osteoporosis
• A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Monotherapy Study of the Efficacy, Safety, and Tolerability of SPT-300 in Ad … Recruiting
  2025-521240-37-00 4 2025-09-11 Major Depressive Disorder (MDD), with or without Anxious Distress
• A Worldwide Study Testing the New Drug Lisaftoclax for Patients with Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma … Recruiting
  2024-514084-26-00 5 2025-08-22 Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphom
• The AIRTIVITY TM Study: A study to find out whether BI 1291583 helps people with bronchiectasis Recruiting
  2024-518589-29-00 5 2025-08-21 Bronchiectasis
• A randomized, placebo-controlled trial to evaluate the safety and efficacy of Debio 4126 in patients with acromegaly previously treated with … Recruiting
  2024-516616-24-00 5 2025-07-23 Acromegaly
• A phase 2 placebo-controlled trial to investigate visugromab in combination with immunochemotherapy (ICT) in first-line treatment of partici … Recruiting
  2024-516792-32-01 4 2025-07-18 Metastatic non-squamous non-small cell lung cancer
• A Study to Learn About the Study Medicine Called Sigvotatug Vedotin in People with Locally Advanced, Unresectable, or Metastatic Non-Small C … Recruiting
  2024-517968-36-00 5 2025-07-08 non-small cell lung cancer
• A phase 1 trial to evaluate the safety, tolerability, pharmacodynamics, pharmacokinetics, and immunogenicity of VIS171 in participants with … Recruiting
  2024-518976-30-00 3 2025-07-02 Systemic lupus erythematosus
• A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with … Recruiting
  2024-513965-38-01 5 2025-06-16 Sjögren's Disease
• An Extension Study to Evaluate Safety, Efficacy, and Durability of Response to ESK-001 for Moderate to Severe Plaque Psoriasis (ONWARD3) Recruiting
  2024-511166-36-00 5 2025-06-13 Moderate to Severe Plaque Psoriasis
• Long-term safety and efficacy study of riliprubart in participants with CIDP Recruiting
  2024-517032-22-00 5 2025-06-10 Immune system diseases.

Showing 49–72 of 590 trials